BenevolentAI Investor Presentation Deck
About us
$300m in platform investment
Board with deep expertise
across Al, drug discovery & development,
pharmaceuticals
Listed on EuroNext Amsterdam
April 2022
Cash runway to Q4 2024
providing sufficient capital for key value
inflection points
TEAM
as at June 2022
Full molecular biology, medicinal
chemistry and in vivo
pharmacology capabilities for
in-house experimentation
BOARD
Baroness Joanna
Shields
CEO & Executive
Director
Jean Raby
Non-Executive
Director
François Nader
Chairman
Jackie Hunter
Non-Executive
Director
Science
Susan Liautaud
Non-Executive
Director
Nigel Shadbolt
Non-Executive
Director
BizOps
350+
World Class
Scientists &
Technologists
Tech
Olivier
Brandicourt
Non-Executive
Director
John Orloff
Non-Executive
Director
Benevolent
4View entire presentation